Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

ASH 2023 Updates on Frontline Therapies in MCL

February 6th 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK Inhibitor–Pretreated R/R MCL

February 2nd 2024

Jonathon B. Cohen, MD, MS, expands on updated data from the BRUIN trial of pirtobrutinib in patients with relapsed BTK-exposed mantle cell lymphoma.

FDA Grants Priority Review to Expand Liso-Cel Indications in R/R Follicular Lymphoma and MCL

January 30th 2024

Liso-cel sBLAs for indications in relapsed/refractory FL and MCL after exposure to a BTK inhibitor have received priority review from the FDA.

Dr Danilov on Using MRD Status to Predict Outcomes in Hematologic Malignancies

January 30th 2024

Alexey Danilov, MD, PhD, discusses the use of minimal residual disease to predict outcomes in patients with follicular lymphoma.

Current Treatment Options in First-Line MCL

January 30th 2024

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

CD19 CAR T Cells Plus Acalabrutinib Shows Early Activity in Relapsed/Refractory MCL

January 29th 2024

CD19 CAR T cell therapy plus acalabrutinib demonstrated early efficacy in patients with relapsed/refractory mantle cell lymphoma.

Dr Pearse on the Use of BTK Inhibitors in Relapsed/Refractory MCL

January 25th 2024

William B. Pearse, MD, discusses the current and future roles of BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Pirtobrutinib Expands MCL Armamentarium, Although Sequencing Questions Remain

January 24th 2024

William Pearse, MD, discusses how the FDA approval of pirtobrutinib for relapsed/refractory mantle cell lymphoma has advanced BTK inhibitor treatment.

BTK Inhibitor–Associated AEs Can Influence Treatment Selection in MCL

January 23rd 2024

William Pearse, MD, discusses the roles of acalabrutinib and zanubrutinib in mantle cell lymphoma, as well as the adverse effect profiles of each agent.

Dr Phillips on Ongoing Research to Address Unmet Needs in Patients With High-Risk MCL

January 17th 2024

Tycel Phillips, MD, discusses the potential advantages of treating patients with relapsed/refractory mantle cell lymphoma in the phase 3 GLOBRYTE trial.

Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL

January 12th 2024

Tycel Phillips, MD, discusses the rationale for the phase 3 GLOBRYTE trial examining glofitamab in patients with relapsed/refractory mantle cell lymphoma.

Dr Danilov on Addressing BTK Inhibitor Resistance in Relapsed/Refractory CLL and MCL

January 12th 2024

Alexey Danilov, MD, PhD, discusses how further research may address unmet needs in chronic lymphocytic leukemia or mantle cell lymphoma.

Acalabrutinib Triplet Shows Early Signals of Activity, Safety in R/R Mantle Cell Lymphoma

December 19th 2023

The combination regimen comprised of acalabrutinib, venetoclax, and obinutuzumab proved to be safe and feasible and to elicit responses in patients with high-risk, relapsed or refractory mantle cell lymphoma.

Relma-Cel Continues to Elicit Responses in Chinese Patients With R/R Mantle Cell Lymphoma

December 19th 2023

Relmacabtagene autoleucel continued to induce responses with acceptable tolerability in Chinese patients with relapsed or refractory mantle cell lymphoma.

Dr Cohen on the Efficacy of Pirtobrutinib in High-Risk Patients With MCL

December 12th 2023

Jonathon B. Cohen, MD, MS, discusses safety and efficacy outcomes with pirtobrutinib in previously treated patients with relapsed/refractory mantle cell lymphoma, as observed in the phase 1/2 BRUIN study.

Ibrutinib Plus Venetoclax Confers PFS, Response Benefit in Relapsed/Refractory MCL

December 12th 2023

Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival vs ibrutinib plus placebo in patients with relapsed/refractory MCL.

Zanubrutinib Triplet Shows Early Promise in Treatment-Naive TP53-Mutant MCL

December 11th 2023

The combination comprised of zanubrutinib, obinutuzumab, and venetoclax elicited high response rates and 2-year progression-free survival rates that compared favorably with historical outcomes achieved with chemoimmunotherapy in high-risk patients with previously untreated mantle cell lymphoma harboring TP53 mutations.

Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

December 10th 2023

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Brexu-Cel Induces Responses in Real-World Population of High-Risk R/R MCL

December 9th 2023

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

Dr Goy on the Influence of High-Risk Features on Treatment Decision-Making in MCL

December 5th 2023

Andre Goy, MD, discusses the prevalence of high-risk clinical features in patients with mantle cell lymphoma and their influence on treatment approaches.